Abstract
Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.
| Original language | English |
|---|---|
| Pages (from-to) | 595-604 |
| Number of pages | 10 |
| Journal | Immunotherapy |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jun 2018 |
Bibliographical note
Publisher Copyright:© 2018 Future Medicine Ltd.
Keywords
- allergic asthma
- CpG-ODN
- nanoparticles
- prophylactic treatment
- Th1 cytokines
- Th2 cytokines
- therapeutic treatment
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology